![]()
|
|
||||||||
J Biol Chem, Vol. 274, Issue 51, 36288-36292, December 17, 1999
From the Department of Neuroscience, Neurobiology, Uppsala University, Box 587 Biomedical Center, S-75123 Uppsala, Sweden
| |
ABSTRACT |
|---|
|
|
|---|
The ERM protein family members ezrin, radixin,
and moesin are cytoskeletal effector proteins linking actin to
membrane-bound proteins at the cell surface. Here we report on the
cloning of myosin regulatory light chain interacting protein (MIR), a
protein with an ERM-homology domain and a carboxyl-terminal RING
finger, that is expressed, among other tissues, in brain. MIR is
distributed in cultured COS cells, in a punctated manner as shown using
enhanced green fluorescent protein (EGFP)-tagged MIR and by staining
with a specific antibody for MIR. In the yeast two-hybrid system and in
transfected COS cells, MIR interacts with myosin regulatory light chain
B, which in turn regulates the activity of the actomyosin complex.
Overexpression of MIR cDNA in PC12 cells abrogated neurite outgrowth induced by nerve growth factor (NGF) without affecting TrkA
signaling. The results show that MIR, a novel ERM-like protein, affects
cytoskeleton interactions regulating cell motility, such as neurite outgrowth.
Dynamic changes in cell shape and movements involve interactions
between proteins in the cytoskeleton and the plasma membrane. Ezrin,
radixin, moesin, and the related tumor suppressor merlin link the actin
cytoskeleton to membrane-bound proteins located at membrane extension
sites, such as microvilli, membrane rufflings, and at cell-cell
contacts (1-3). ERM1
proteins are also involved in cell adhesion, influencing the redistribution of various cell adhesion molecules, such as ICAM-1 (4,
5). The amino-terminal domain of ERM proteins, comprising about 300 amino acids, is conserved among the different proteins and merlin and
exhibits a high degree of sequence similarity (1-3). This amino
terminus is related to proteins in the large band 4.1 protein
superfamily (6), including some protein tyrosine phosphatases (7) and
talin (8), and it is thought to bind to membrane proteins. In contrast,
the interaction of ERM proteins with F-actin seems to involve both the
amino- and carboxyl-terminal region (5). Merlin, however, lacks the
F-actin binding site in the carboxyl terminus, but binds it in a
different manner (9).
ERM proteins are present in a wide variety of tissues, notably in
epithelial cells in culture (10). In contrast to other tissues, less is
known about the function of ERM proteins in the nervous system. During
development and regeneration, neurons grow over large distances in a
process controlled by extrinsic factors and cytoskeleton interactions.
Some ERM proteins have been found in the growth cones of neuronal cells
(11, 12), suggesting an effect on neurite outgrowth. Indeed, recently
it was shown by an antisense approach, that radixin and moesin are
important for growth cone morphology and motility (13). Although
important for dynamic interactions between cytoskeleton and membranes,
the mechanism by which ERM proteins mediate their effects on cell motility is not fully understood (5). In this study, we have identified
a novel ERM-like protein, called myosin regulatory light chain
interacting protein (MIR), that binds to the myosin regulatory light
chain B (MRLC) (14) and may directly influence cell movements. To study
the effect of MIR on cell motility, we have measured neurite outgrowth
in PC12 cells which was dramatically inhibited by overexpression of
MIR.
Cloning of MIR--
A search in GenBankTM for
expression sequence tag cDNAs (EST) of novel members of the
inhibitory of apoptosis protein (IAP) gene family (15) resulted in an
EST sequence from human lung (accession number T63512) with a RING
finger similar to those found in IAP proteins. A 375-base pair probe,
corresponding to the EST sequence, was amplified by PCR and used for
screening a Northern Blot Analysis--
Multiple tissue Northern blots
(CLONTECH) were hybridized for 2 h at 37 °C
using the Express hybridization solution (CLONTECH) and the MIR cDNA probe labeled with [32P]dCTP
(Rediprime, Amersham Pharmacia Biotech). Filters were washed in 2×
SSC, 0.05% SDS for 30 min and in 0.1× SSC, 0.1% SDS for 40 min at
room temperature. The levels of MIR mRNA were analyzed using a
PhosphoImager (Molecular Dynamics), and compared with those of
Yeast Two-hybrid System--
The full-length coding sequence of
MIR was fused to the GAL4 DNA-binding domain (GALDB) in the pYTH6 bait
vector and integrated into the genome of the yeast strain, Y190. The
resulting Y190:pYTH6-MIR strain was transformed with an expression
cDNA library from HeLa cells (CLONTECH), fused
to the GAL4 activation domain (GAL4AD) in the pGAD-GH vector (16).
4 × 106 transformants were screened for activation of
the His-3 reporter gene on a medium deficient in the amino
acids His, Trp, and Leu and supplemented with 25 mM
3-aminotriazole. Colonies appearing within 3-5 days were subjected to
a Cell Culture and Assay for Neurite Outgrowth--
Rat
pheochromocytoma PC12 cells were maintained in Dulbecco's modified
Eagle's medium supplemented with 5% horse serum and 5% fetal bovine
serum. Cells were transfected with 10 µg of pcDNA3.1 (Invitrogen)
expressing MIR cDNA by the calcium phosphate method (17), and
stable clones were selected using G418 (600 µg/ml, Life
Technologies). PC12 cells were transiently transfected with a control
vector, encoding the enhanced green fluorescence protein (EGFP,
CLONTECH), or with the fusion vector, EGFP-MIR
expressing full-length MIR in frame with EGFP, using the Fugene reagent
(Roche Molecular Biochemicals). The cellular localization of GFP in
living cells was analyzed with a Zeiss Axiovert microscope and an
attached Hamamatsu camera. To study neurite outgrowth, PC12 cells were plated onto collagen-coated (Sigma) culture plates, and 50 ng/ml NGF
added for two days. Neurite outgrowth was estimated by counting the
number of positive PC12 cells exhibiting neurites 2-fold longer than
the cell diameter (17). Statistical analysis was done by Student's
t test.
Immunocytochemistry and MIR Antibody--
A specific antipeptide
antibody to MIR (amino acid sequence, QQTRVLQEKLRKLKEAMLC) was raised
in rabbits using standard procedures. The purified antibody recognized
recombinant MIR in Western blots (data not shown). Cells were fixed for
10 min using 4% paraformaldehyde, washed with phosphate-buffered
saline, and blocked overnight with skim milk (18). The MIR antibody,
diluted 1:100, was added and incubated overnight at 4 °C. After
washing, a secondary biotinylated anti-rabbit antibody (diluted 1:200,
Dako) was added and incubated for 2 h at room temperature,
followed by addition of the avidin-biotin complex (Vector
Laboratories). The signals were visualized using diaminobenzidine
(Sigma) as a chromogen.
Immunoprecipitation and Western Blotting--
Monkey kidney
COS-7 cells were cultured in DMEM supplemented with 10% fetal bovine
serum. Cells were co-transfected with histidine6 (His)-tagged MRLC expression vector (Invitrogen) and with the hemagglutinin (HA)-tagged MIR, pJ3H vector. After 24 h, cells were
lysed in ice-cold RIPA lysis buffer (phosphate-buffered saline, 0.1%
SDS, 0.5% sodium deoxycholate, 1% Nonidet P-40) supplemented with a
protein inhibitor mixture (Boehringer-Mannheim) and 100 µM sodium orthovanadate (Sigma). The lysate was
precleared by centrifugation, and immunoprecipitation was carried out
using an anti-HA antibody (Boehringer-Mannheim). The antibody-protein complex formed was bound to protein A-Sepharose (Amersham Pharmacia Biotech, Uppsala) and washed three times with RIPA buffer. The beads
were suspended and boiled in SDS-loading buffer, and the eluate loaded
onto a 12% SDS acrylamide gel (18). The gel was blotted onto a
polyvinylidene difluoride membrane (Amersham Pharmacia Biotech) and
incubated with anti-His (CLONTECH) and anti-HA
antibodies (Boehringer-Mannheim). The signals were visualized using the
enhanced chemiluminescence method.
TrkA Phosphorylation--
Control and MIR overexpressing PC12
cells were stimulated with NGF for 5 min. Cells were lysed in buffer A,
containing 20 mM HEPES, pH 7.4, 125 mM NaCl,
1% Triton X-100, 10 mM EDTA, 2 mM EGTA, 2 mM sodium orthovanadate, 50 mM NaF, 20 mM ZnCl2, 10 mM sodium
pyrophosphate, 1 mM phenylmethylsulfonyl fluoride, and 5 µg/ml leupeptin (19). The lysates were incubated with anti-Trk antibody (a kind gift from Dr. D. Kaplan, Montreal Neurological Institute) followed by incubation with protein A-Sepharose. The Sepharose beads were washed three times with buffer A, once with 0.5 M LiCl, 0.1 M Tris, pH 7.5, and once with 0.1 M NaCl, 1 mM EDTA, 2 mM Tris, pH
7.5. SDS-loading buffer was added, and proteins were resolved on a 10%
SDS-polyacrylamide gel electrophoresis. The gel was blotted as
described above, and TrkA phosphorylation was analyzed using an
anti-phosphotyrosine antibody (Transduction Laboratories).
MIR Is a Novel ERM-homology Protein--
Using a human fetal brain
library to screen for novel genes, we cloned a cDNA encoding a
novel protein with an open reading frame of 445 amino acids, and two
distinct protein homology regions: an amino-terminal ERM-homology
domain, and a RING finger at the carboxyl-terminal end (20). The
complete amino acid sequence of human MIR is depicted in Fig.
1, together with an alignment of the
ERM-homology region of the ERM proteins and merlin. The amino-terminal
region of MIR exhibits the highest degree of similarity to ezrin and
merlin, 25 and 28% identity, respectively (Fig. 1b). The
RING finger in MIR resembles that of other proteins (Fig. 1) involved
in regulation of cell growth and apoptosis, including proteins of the
IAP family such as XIAP and c-IAP2 (15).
MIR mRNA Is Expressed in Various Human Fetal and Adult
Tissues--
Previous studies have shown that the ERM proteins are
expressed in many different tissues. Fig.
2 shows that MIR mRNA, with a size of
about 3 kilobases, is present in various human tissues, including fetal
and adult brain. The most prominent expression was seen in placenta and
fetal lung, with approximately equal levels of MIR mRNA in other
tissues.
Distribution of MIR in Cultured COS Cells--
COS-7 cells were
transiently transfected with MIR cDNA expressing EGFP at the
amino-terminal end for visualization. The EGFP-MIR fusion protein
showed a punctated pattern of GFP fluorescence in transfected COS-7
cells, whereas the control EGFP vector showed a homogenous distribution
of green fluorescence throughout the cytoplasm (Fig.
3). The distribution of fluorescence of
EGFP-MIR in COS cells is similar to that observed previously for ERM
proteins fused to GFP (5). To study the localization of endogenous MIR, we stained COS cells with an antibody specific for MIR, which gave rise
to a pattern similar to that obtained with EGFP-MIR (Fig.
3c). These results demonstrate that MIR distributes in a distinct punctate pattern within COS-7 cells, indicative of an association with the cytoskeleton.
MIR Interacts with MRLC--
To reveal the function of MIR, we
screened a HeLa cell cDNA library using the yeast two-hybrid system
and identified MRLC (14) as an interactor for MIR. A qualitative assay
for MIR Inhibits Neurite Outgrowth of PC12 Cells but Does Not Affect
TrkA Phosphorylation--
MRLC is part of the protein complex
controlling the driving force for myosin molecules which control the
actomyosin complex (21). We were therefore interested in studying
whether MIR affects cell motility. PC12 cells were treated with NGF
(17), and whereas control PC12 cells exhibited a profuse outgrowth of
neurites after 50 ng/ml NGF, MIR stably transfected cells did not (Fig.
4b). The inhibition of neurite outgrowth by MIR
overexpression could not be overcome by higher NGF concentrations (data
not shown).
To study whether the PC12 cells overexpressing MIR are defective in
their response to NGF, we investigated the potential involvement of the
NGF receptor, TrkA using a phosphorylation assay (19). Fig.
4c shows that TrkA is tyrosine phosphorylated by NGF in both control and MIR overexpressing cells, excluding an alteration in
receptor activation in these cells. Likewise, the immediate early gene,
cFos was equally stimulated by NGF in both types of cells (data not
shown). These results lend credence to the view that NGF acts normally
in MIR overexpressing cells and that the absence of an appreciable
degree of neurite outgrowth by NGF in MIR transfected cells occurs
downstream of TrkA. To substantiate the results obtained using stable
cell lines, PC12 cells were transiently transfected with the EGFP-MIR
expression vector. The results showed that overexpression of MIR
significantly inhibited neurite outgrowth stimulated by NGF (Fig.
4d). Quantification of the data showed that MIR transfected
cells had significantly less neurites compared with control PC12 cells
(Fig. 4e).
In this study we have cloned MIR, a novel member of the ERM
protein family which is expressed in a variety of different human tissues. In addition to the amino-terminal ERM homology domain, MIR has
a carboxyl-terminal RING finger similar to other proteins involved in
regulating growth and survival of cells (20). The ERM and the RING
finger domains constitute structural motifs which probably mediate
important protein-protein interactions. Using the yeast two-hybrid
system, we identified MRLC as a protein interacting with MIR,
suggesting a possible role of MIR in the actomyosin complex.
ERM proteins associate with proteins both in the plasma membrane and in
the cytoskeleton, taking part in the co-ordination of cell
motility. According to the present results, an essential function for
MIR in transfected PC12 is to influence neurite outgrowth, probably by
influencing cytoskeletal components involved in cell motility. MIR
interacts with MRLC, which regulates the activity of the actomyosin
complex in muscle as well as in nonmuscle cells (21). Two isoforms of
MRLC are present in brain tissue and in cultured neuroblasts (22).
Evidence has recently been provided for the involvement of myosin in
neurite outgrowth (23). Neuronal cells express different forms of
myosin including conventional myosin II, present at the leading edge of
the growth cones (24). Mouse neuroblastoma cells express both myosin
IIA and myosin IIB isoforms, but only the latter seems to be involved
in neurite extension (24). In view of the present finding, it is
reasonable to assume that MIR, via its interaction with MRLC, can
inhibit the driving force of myosin, which controls the actomyosin
complex. Previous studies have shown an effect of radixin and moesin on growth cone motility and process formation in neurons (11, 12). Radixin
was shown to redistribute to the growth cones following NGF stimulation
(11). These results suggest an important function for different
ERM-like proteins in the control of neurite outgrowth, which may
involve an interaction with MIR.
The activity of actomyosin complex is known to be regulated by the
phosphorylation state of MRLC, which is influenced by the myosin light
chain kinase and by the corresponding phosphatase (25). Increased MRLC
phosphorylation leads to enhanced cell contractility and to increased
calcium sensitivity in smooth muscle cells (26). A similar regulation
of myosin activity probably occurs in neurons. Recent evidence suggests
a critical role for Rho, belonging to the small GTPase Rho family of
proteins (27) and for its associated Rho p160 kinase (ROCK) in
mediating MRLC phosphorylation (26). It was recently shown that
agonist-induced or enhanced Rho/ROCK activity is sufficient for
mediating neurite retraction and cell rounding of neuroblastoma cells
in culture (28). It was suggested that Rho/ROCK activity tonically
inhibits cell process extensions via activation of actinomyosin
contractility and suppression of the assembly of intermediate filaments
and microtubules (28). Previous studies have suggested a role for ERM
proteins in the activation cascade induced by Rho (5) via a conserved
threonine in the carboxyl-terminal region of ERM proteins, which is
phosphorylated by ROCK (29). On the other hand, ERM proteins are
thought to contribute to the activation of Rho by sequestering the Rho
GDP dissociation inhibitor, which in turn binds the inactive form of
Rho (30).
In view of these mutual interactions between the Rho family members and
ERM proteins, it is possible that the function of MIR is linked to
alterations in Rho activity. Indeed, microinjection of active ROCK
kinase in PC12 cells leads to neurite retraction (31). This is
analogous to the effect observed for MIR in transfected PC12 cells, and
suggests that MIR functions in parallel to Rho/ROCK in inhibiting
neurite extension. The mechanism by which MIR acts may indirectly
involve changes in MRLC phosphorylation thereby hindering cytoskeleton
interactions promoting neurite outgrowth.
MIR may have additional functions in cells, acting as a stabilizing
factor for the cytoskeleton by cross-linking various protein components
important for the attachment/detachment reactions required for cell
motility. In keeping with such a notion, we have recently obtained
evidence for the interaction of MIR with other regulatory proteins
affecting the cytoskeleton. The nature of these proteins and the role
of MIR in regulating cell motility in other cell types than neurons are
currently under investigation.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
gt10 human fetal brain library
(CLONTECH). Hybridization was carried out overnight
at 42 °C in 50% formamide, 6× SSC, 5× Denhardt's, and 0.5% SDS,
followed by washing for 10 min in 2× SSC, 0.5% SDS, for 15 min in
0.2× SSC, 0.5% SDS, and finally for 15 min in 0.2× SSC, 0.5% SDS at
50 °C. A positive phage of 1650 base pairs was cloned into the
Bluescript pKS vector and sequenced using an automated DNA Sequencer
(Applied Biosystems). The nucleotide sequence encodes a putative
protein with an open reading frame of 445 amino acids and was named
MIR. The MIR sequence has been submitted to the GenBankTM
(accession number, AF187016).
-actin mRNA.
-galactosidase filter lift assay (16), and the positive clones
obtained were rescued into Escherichia coli and
retransformed into the Y190:pYTH6-MIR strain to confirm the
interaction. The clones were sequenced, and two were identified as the
myosin regulatory light chain B (MRLC). Deletions of MIR cDNA were
subcloned into the pYTH6 vector using a polymerase chain reaction-based
strategy. These constructs were sequenced and studied for the
interaction with MRLC.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (75K):
[in a new window]
Fig. 1.
Structure of human MIR and sequence
comparison. a, the deduced amino acid sequence of human
MIR. Numbers on the right indicate the amino acid residue
position. b, sequence alignment of amino acids 1-282 of MIR
with ERM proteins and merlin using the GCG Pile-Up program. Black
boxes, identical residues; gray boxes, similar residues
to MIR. c, alignment of MIR with some known RING finger
proteins. Black boxes show the conserved cysteine and
histidine in the RING finger motif (C3-H-C4). Gray boxes
denote conserved amino acids at other positions. c-IAP2,
human inhibitor of apoptosis protein 2; XIAP, X-chromosome
linked inhibitor of apoptosis protein; c-CBL, cbl
proto-oncoprotein; CGR19, human cell growth regulator p19;
PML, promyelocytic leukemia protein; and RFP, ret
finger protein.

View larger version (78K):
[in a new window]
Fig. 2.
Tissue distribution of human MIR
mRNA. Northern blot analysis was done using Multiple Tissue
Northern blots (CLONTECH) as described under
"Experimental Procedures." Expression of
-actin was used as a
standard. a, fetal; b, adult tissues.

View larger version (33K):
[in a new window]
Fig. 3.
Distribution of MIR in COS cells.
a-b, COS-7 cells were transiently transfected with the EGFP
control vector (a) or with the fusion construct, EGFP-MIR
(b). After 24 h, living cells were observed using a
Zeiss Axiovert microscope linked to a Hamamatsu camera. Scale
bar, 30 µm. c, COS-7 cells stained with an anti-MIR
antibody. Cells were fixed and immunocytochemistry was performed using
an antibody specific for MIR as described under "Experimental
Procedures." The resulting immunocomplex was visualized using
diaminobenzidine as a chromogen. Scale bar, 30 µm.
-galactosidase showed that MRLC exhibited a strong binding to
MIR, whereas other proteins such as merlin or XIAP did not interact
(Table I). To characterize the binding
site of MIR, deletions were made and analyzed further within the yeast
system. None of the deletion constructs interacted with MIR, indicating
that the whole molecule is required for binding (Table I). To confirm
the interaction of MIR with MRLC, we co-transfected COS-7 cells with
expression vectors carrying the cDNAs with a recognition sequence
tag. Using an anti-HA antibody, we were able to show
co-immunoprecipitation of MRLC with MIR (Fig.
4a). This data confirms that
an interaction between these proteins occurs also in mammalian
cells.
Yeast two-hybrid interactions between different domains of the MIR
protein and
MRLC

View larger version (50K):
[in a new window]
Fig. 4.
MIR interacts with MRLC and inhibits neurite
outgrowth. a, COS-7 cells were transiently transfected with
expression vectors encoding HA-tagged MIR and His-tagged MRLC. Cells
were lysed after 24 h, and anti-HA immunoprecipitates were
analyzed for the presence of MIR and MRLC by Western blotting.
b, control (left panel) and PC12 cells stably
overexpressing MIR (right panel) were treated for 2 days
with 50 ng/ml NGF and observed for neurite outgrowth using a Zeiss
microscope. The picture shows a typical experiment that was repeated
four times on three different cell clones. Scale bar, 50 µm. c, control and MIR overexpressing PC12 cells were
treated for 5 min with 50 ng/ml NGF. Cell lysates were prepared and
analyzed for TrkA phosphorylation as described under "Experimental
Procedures." d, PC12 cells were transiently transfected
with the control EGFP vector (left panel) or with the fusion
construct, EGFP-MIR (middle panel). Right panel
is a phase contrast picture of the same area with an arrow
pointing to the transfected cell. Cells were stimulated for 2 days with
50 ng/ml NGF, and were observed for neurite outgrowth using a Zeiss
Axiovert microscope linked to a Hamamatsu camera. Scale bar,
30 µm. e, quantification of neurite outgrowth after NGF.
The number of transfected PC12 cells having neurites 2-fold longer than
the cell diameter were counted. Values represent mean ± S.E. of
three independent experiments with a total number of 100 fluorescent
cells analyzed. p
0.001 for Control
versus MIR. MIR, cells transfected with EGFP-MIR.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
| |
ACKNOWLEDGEMENT |
|---|
We thank Pontus Aspenström for helpful discussions.
| |
FOOTNOTES |
|---|
* This study was supported by the Swedish Cancer Foundation (Cancerfonden) and by a EU-BIOTECH grant.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EMBL Data Bank with accession number(s) AF187016.
To whom correspondence should be addressed. Tel.: ++46 18
4714435; Fax: ++46 18 559017; E-mail:
dan.lindholm@neuro.uu.se.
| |
ABBREVIATIONS |
|---|
The abbreviations used are: ERM proteins, ezrin, radixin, moesin protein family; EGFP, enhanced green fluorescent protein; HA, hemagglutinin; IAP, inhibitory of apoptosis protein; MIR, myosin regulatory light chain interacting protein; MRLC, myosin regulatory light chain B; NGF, nerve growth factor; PBS, phosphate-buffered saline; ROCK, Rho p160 kinase.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Bretscher, A., Reczek, D., and Berryman, M. (1997) J. Cell Sci. 110, 3011-3018[Abstract] |
| 2. | Tsukita, Sa, Yonemura, S., Tsukita, and Sh. (1997) Trends Biochem. Sci. 22, 53-58[CrossRef][Medline] [Order article via Infotrieve] |
| 3. | Vaheri, A., Carpén, O., Heiska, L., Helander, T. S., Jääskeläinen, J., Majander-Nordenswan, P., Sainio, M., Timonen, T., and Turunen, O. (1997) Curr. Opin. Cell Biol. 9, 659-666[CrossRef][Medline] [Order article via Infotrieve] |
| 4. | Helander, T. S., O., Carpén, O., Turunen, O., Kovanen, P. E., Vaheri, A., and Timonen, T. (1996) Nature 382, 265-268[CrossRef][Medline] [Order article via Infotrieve] |
| 5. | Mangeat, P., Roy, C., and Martin, M. (1999) Trends Cell Biol. 9, 187-192[CrossRef][Medline] [Order article via Infotrieve] |
| 6. | Gould, K. L., Bretscher, A., Esch, F. S., and Hunter, T. (1989) EMBO J. 8, 4133-4142[Medline] [Order article via Infotrieve] |
| 7. |
Zhang, S. H.,
Eckberg, W. R.,
Yang, Q.,
Samatar, A. A.,
and Tonks, N. K.
(1995)
J. Biol. Chem.
270,
20067-20072 |
| 8. | Rees, D. J. G., Ades, S. E., Singer, S. J., and Hynes, R. O. (1990) Nature 347, 685-689[CrossRef][Medline] [Order article via Infotrieve] |
| 9. | Xu, H.-M., and Gutmann, D. H. (1998) J. Neurosci. Res. 51, 403-415[CrossRef][Medline] [Order article via Infotrieve] |
| 10. |
Sato, N.,
Funayama, N.,
Nagafuchi, A.,
Yonemura, S.,
Tsukita,
Sa,
Tsukita,
and Sh.
(1992)
J. Cell Sci.
103,
131-143 |
| 11. | Gonzalezagosti, C., and Solomon, F. (1996) Cell Motil. Cytoskeleton 34, 122-136[CrossRef][Medline] [Order article via Infotrieve] |
| 12. | Amieva, M. R., and Furthmayr, H. (1995) Exp. Cell. Res. 219, 180-196[CrossRef][Medline] [Order article via Infotrieve] |
| 13. |
Paglini, G.,
Kunda, P.,
Quiroga, S.,
Kosik, K.,
and Cáceres, A.
(1998)
J. Cell Biol.
143,
443-455 |
| 14. |
Taubmann, M. B.,
Grant, J. W.,
and Nadal-Ginard, B.
(1987)
J. Cell Biol.
104,
1505-1513 |
| 15. | Clem, R. J., and Duckett, C. S. (1997) Trends Cell Biol. 7, 337-339[Medline] [Order article via Infotrieve] |
| 16. | Aspenström, P., and Olson, M. F. (1995) Methods Enzymol. 256, 228-241[Medline] [Order article via Infotrieve] |
| 17. | Inagaki, N., Thoenen, H., and Lindholm, D. (1995) Eur. J Neurosci. 7, 1125-1133[CrossRef][Medline] [Order article via Infotrieve] |
| 18. | Korhonen, L., Hamnér, S., Olsson, P.-A., and Lindholm, D. (1997) Eur. J. Neurosci. 9, 2489-2496[CrossRef][Medline] [Order article via Infotrieve] |
| 19. |
Frisén, J.,
Risling, M.,
Korhonen, L.,
Zirrgiebel, U.,
Johansson, C. B.,
Cullheim, S.,
and Lindholm, D.
(1998)
J. Neurosci.
18,
5714-5722 |
| 20. | Freemont, P. S. (1993) Ann. N. Y. Acad. Sci. 684, 174-192[Medline] [Order article via Infotrieve] |
| 21. | Howard, J. (1997) Nature 389, 561-567[CrossRef][Medline] [Order article via Infotrieve] |
| 22. | Feinstein, D. L., Durand, M., and Milner, R. J. (1991) Mol. Brain Res. 10, 97-105[Medline] [Order article via Infotrieve] |
| 23. | Hasson, T., and Mosseker, M. S. (1997) Curr. Opin. Neurobiol. 7, 615-623[CrossRef][Medline] [Order article via Infotrieve] |
| 24. |
Wylie, S. R.,
Wu, P.-J.,
Patel, H.,
and Chantler, P. D.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
12967-12972 |
| 25. | Somlyo, A. P., and Somlyo, A. V. (1994) Nature 372, 231-236[CrossRef][Medline] [Order article via Infotrieve] |
| 26. | Uehata, M., Ishizaki, T., Satoh, H., Ono, T., Kawahara, T., Morishita, T., Tamakawa, H., Yamagami, K., Inui, J., Maekawa, M., and Narumiya, S. (1997) Nature 389, 990-994[CrossRef][Medline] [Order article via Infotrieve] |
| 27. | Machesky, L. M., and Hall, A. (1996) Trends Cell Biol. 6, 304-310[CrossRef][Medline] [Order article via Infotrieve] |
| 28. |
Hirose, M.,
Ishizaki, T.,
Watanabe, N.,
Uehata, M.,
Kranenburg, O.,
Moolenar, W. H.,
Matsumura, F.,
Maekawa, M.,
Bito, H.,
and Narumiya, S.
(1998)
J. Cell Biol.
141,
1625-1636 |
| 29. |
Matsui, T.,
Maeda, M.,
Doi, Y.,
Yonemura, S.,
Amano, M.,
Kaibuchi, K.,
Tsukita, S.,
and Tsukita, S.
(1998)
J. Cell Biol.
140,
647-657 |
| 30. |
Takahashi, K.,
Sasaki, T.,
Mammoto, A.,
Takaishi, K.,
Kameyama, T.,
Tsukita, S.,
Tsukita, S.,
and Takai, Y.
(1997)
J. Biol. Chem.
272,
23371-23375 |
| 31. |
Katoh, H.,
Aoki, J.,
Ichikawa, A.,
and Negishi, M.
(1998)
J. Biol. Chem
273,
2489-2492 |
This article has been cited by other articles:
![]() |
S. Landais, S. Landry, P. Legault, and E. Rassart Oncogenic Potential of the miR-106-363 Cluster and Its Implication in Human T-Cell Leukemia Cancer Res., June 15, 2007; 67(12): 5699 - 5707. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. C. Bornhauser, P.-A. Olsson, and D. Lindholm MSAP Is a Novel MIR-interacting Protein That Enhances Neurite Outgrowth and Increases Myosin Regulatory Light Chain J. Biol. Chem., September 12, 2003; 278(37): 35412 - 35420. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Kubo, T. Yamashita, A. Yamaguchi, H. Sumimoto, K. Hosokawa, and M. Tohyama A Novel FERM Domain Including Guanine Nucleotide Exchange Factor Is Involved in Rac Signaling and Regulates Neurite Remodeling J. Neurosci., October 1, 2002; 22(19): 8504 - 8513. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |